CLOs on the Move

Coeptis Therapeutics

www.coeptistx.com

 
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively "Coeptis"), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis` product portfolio and rights are highlighted by a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and intellectual property and knowhow related to the GEAR™ cell therapy and companion diagnostic platforms, which Coeptis is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet. Coeptis` business model is designed around maximizing the ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.coeptistx.com
  • 105 Bradford Road Suite 420
    Wexford, PA USA 15090
  • Phone: 724.934.6467

Executives

Name Title Contact Details
Christine Sheehy
Vice President of Compliance and Corporate Secretary Profile

Similar Companies

Oread

Oread is a Lawrence, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

EMD Electronics

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials.

LEO Pharma

LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in more than 100 countries globally, LEO Pharma supports people in managing their skin conditions. Founded in 1908 and owned by the LEO Foundation, the healthcare company has devoted decades of research and development to delivering products and solutions to people with skin conditions. LEO Pharma is headquartered in Denmark and employs around 5,000 people worldwide.

Ratio Therapeutics

A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer. Ratio Therapeutics` Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.

Whitman-Walker Health

Social Media Commenting Policy Welcome! Whitman-Walker maintains social media channels as a service to our supporters who wish to keep updated on news from WWH and possibly share information with one another. We are glad to have you join us! We ...